National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
April 20, 2010 • Volume 7 / Number 8


Study of Tamoxifen And Raloxifene logoLong-term Follow-up Confirms Breast Cancer Risk Reduction with Raloxifene

The drugs raloxifene (Evista) and tamoxifen both substantially reduce the risk of breast cancer in women at high risk for the disease, but raloxifene causes fewer and less-severe side effects, according to the long-term results of a large breast cancer prevention trial presented yesterday at the American Association for Cancer Research (AACR) annual meeting in Washington, DC. Read more > >


Director's Update: An Unexpected Opportunity,
a Welcome Honor

The Director’s Update for this issue was taken from the remarks delivered by NCI Director Dr. John E. Niederhuber on Sunday, April 18, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC. Dr. Niederhuber was presented with the AACR Award for Distinguished Public Service. Read more > >

Guest Commentary by Dr. Carolyn Clancy: Focusing the Research Enterprise on the Patient

The director of AHRQ discusses how patient-centered research improves the quality of care for cancer patients Read more > >




  • FDA Update

    • Erlotinib Approved as Maintenance Therapy for Non-small Cell Lung Cancer
    • Long-term Shortage of Cancer Drug Mustargen Expected
    • Changes Announced in Approval Process for Certain Radiation Therapy Devices
  • Legislative Update

    • House Committee Convenes Hearing on Smokeless Tobacco
  • Update

    • NCI Issues Updated Cancer Trends Progress Report
    • SEER Program Releases New CSR Data
    • NCI Launches “New on” E-mail List
  • Notes

    • New Cancer Signatures Funding
      Opportunity Announced
    • Learn About NCI Resources and Opportunities at BIO International Convention
    • NCI and Republic of Croatia Formalize Alliance

Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information about cancer, call 1-800-4-CANCER or visit

NCI Cancer Bulletin staff can be reached at

Next Section >